Rivpra Formulation Pvt. Ltd: drug alert entries
Batches made by Rivpra Formulation Pvt. Ltd (as named by CDSCO) that appear in CDSCO drug alerts: 12 entries. For spurious entries, the named company may be the brand owner rather than the actual maker.
Bromhexine Hydrochloride, Terbutaline Sulphate, Guaiphenesin & Menthol SyrupNSQ
Result: The sample does not conform to claim as per Patent and Proprietary in respect to the Assay of Bromhexine Hydrochloride, Terbutaline Sulphate
Sodium Bicarbonate Tablets USP 1000 mgNSQ
Result: The sample does not conform to claim as per USP 2025 in respect to the Test of Description.
Sodium Bicarbonate Tablets IP 500 mgNSQ
Result: The sample does not conform to the IP standards with respect to the test Disintegration
Sodium Bicarbonate Tablets I.P. 1000 mgNSQ
Result: The sample does not conform to I.P (Addendum 2024) with respect to the Test of Disintegration
Bromhexine Hydrochloride, Terbutaline Sulphate, Guaiphenesin & Menthol SyrupNSQ
Result: The sample does not conform to claim as per Patent and Proprietary in respect to the Assay of Bromhexine Hydrochloride.
Teneligliptin & Metformin Hydrochloride Extended Release tablets IPNSQ
Result: The sample does not conform to I.P. with respect to the Dissolution and Assay of Teneligliptin
Hydroxychloroquine Sulphate Tablets IP 200mg (HYDROXYMEN-200)NSQ
Result: Dissolution as per IP
Ambroxol Hydrochloride, Guaiphenesin & Terbutaline Sulphate SyrupNSQ
Result: Description
Sodium Bicarbonate Tablets I.P. 1000 mgNSQ
Result: The sample received does not conform to I.P. 2022 with respect to the test for Disintegration
Teneligliptin & Metformin Hydrochloride Extended-release Tablets 20mg and 500mgNSQ
Result: The sample received does not conform to I.P. 2022 with respect to the test of Dissolution (Teneligliptin) and Assay /Content of Teneligliptin
Teneligliptin & Metformin Hydrochloride Extended-release Tablets 20mg and 500mgNSQ
Result: The sample received does not conform to I.P. 2022 with respect to the test for Dissolution (Teneligliptin)
Clopidogrel Tablets IP 75 mgNSQ
Result: The sample received does not conform to IP 2022 specification with respect to the Description only.